Our Principal, Yolanda Wang, just returned from the 1st China Pharmaceutical Innovation Conference (CPIC 2026) in Shanghai, held from July 22–24!

It was a pleasure to attend CPIC 2026 together with fellow HKBMIA members and connect with biotech innovators from around the world. Many thanks to HKBMIA for the invitation and the opportunity to engage with industry partners. Hong Kong continues to play an important role in connecting Mainland China with the global life sciences community.

Bringing together over 10,000 participants, CPIC highlighted the strong momentum behind cross-border biopharma innovation and collaboration. It was great to see so many discussions focused on advancing healthcare innovation and building new partnerships across borders. The strong presence of AI-related healthcare and drug development initiatives was particularly impressive and reflected the rapid evolution of China’s innovation ecosystem. As IP professionals, we are reminded of the important role that IP plays in supporting innovation and bringing new technologies to market.

Our Past Events

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

16 June 2026

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

5 June 2026

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2 June 2026

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

8 May 2026

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

8 May 2026

Eagle IP to Attend INTA 2026 Annual Meeting in London

2 May 2026

Recommended Insights

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

28 February 2024
A Closer Look at the New Presumed Receipt Date Calculation Background China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how […]
Read more >

No More Hindsight Bias: China’s Supreme People's Court Reins in Patent Inventiveness Assessments

25 June 2026
For foreign applicants navigating patent litigation or invalidation in China, a common frustration is hindsight bias. Too often, CNIPA or lower courts strip down a patent into isolated technical features, find those features across disparate prior art references, and declare the invention to be "obvious". To counter such hindsight reasoning, the core criterion has always […]
Read more >

IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard

1 June 2026
In theory China's inventorship standard is similar to others around the world. An inventor is anyone who "makes creative contributions to the substantive features" of an invention. But what does this mean, and how does one apply this standard? Up to this point, this issue hasn't really been litigated much in China (at least according […]
Read more >

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

24 May 2021
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
Read more >
Top crossarrow-right